William Maughan
Stock Analyst at Canaccord Genuity
(2.25)
# 1,045
Out of 4,479 analysts
7
Total ratings
40%
Success rate
2.24%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $11.37 | +58.31% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $18.26 | +130.01% | 2 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $10.41 | +53.70% | 1 | Jul 6, 2022 | |
| BNTX BioNTech SE | Assumes: Buy | $192 | $78.76 | +143.78% | 1 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $19.81 | +202.88% | 1 | Jul 6, 2022 |
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $11.37
Upside: +58.31%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $18.26
Upside: +130.01%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $10.41
Upside: +53.70%
BioNTech SE
Jul 6, 2022
Assumes: Buy
Price Target: $192
Current: $78.76
Upside: +143.78%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $19.81
Upside: +202.88%